To aid in this complicated task the Eviti Evidence-based Medical Library, which is updated regularly with new standards of care identified in the latest research from recognized institutions—including reports from the FDA, NCCN, and more. With Eviti, NantHealth makes validating high-quality, high-value treatments as easy as a few clicks.

Validate Treatments Intelligently and Automatically

Today, the number of factors both providers and payers must consider before aligning on a treatment plan is staggering. That’s where NantHealth’s technology comes into play. NantHealth’s Eviti Connect enables providers to easily compare thousands of evidence-based, nationally-recognized treatments and clinical trials, and payers to validate those treatments for appropriate reimbursement.

This increased visibility and collaboration simplifies, streamlines, and speeds the crucial, time-sensitive process of care validation.

Treatment Validation Solutions

Give Clinicians Confidence

  • Accurate Information – Provide access to treatments based on the latest research and evidence backed by nationally-recognized institutions.
  • Streamline Approvals – Automatically validate evidence-based treatments, eliminating admin burden and boosting efficiency.
  • Optional Preferences – Drive to more cost-effective therapies with configurable drug preferences.
  • Automate Authorization – Streamline the approval process to start care faster, while reducing administrative burden.
  • Collaborate with Confidence – Evidence-based treatments give all stakeholders peace of mind.

Empower Your Provider Network

  • Access the Latest Research – Treatments are vetted and validated in near real-time to provide your clinicians with the most accurate information.
  • Evidence-based Options – Every treatment in the Eviti Library is endorsed by leading authorities in the field of cancer research.
  • Simplify Workflow – Eliminate time-consuming administrative and information-gathering burdens that cut into your providers’ ability to deliver superior care.

References: 1 Abernethy et al. Journal of Clinical Oncology 2010;28:4268-4274.